NCT06520189

Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To detect value of F-18FDG PET/CT as a non-invasive method for the prediction of EGFR mutations in lung cancer patients.

Detailed description

* Globally, lung cancer cases and deaths are rising. In 2018, GLOBOCAN estimated 2.09 million new cases (11.6% of total cancer cases) and 1.76 million deaths (18.4% of total cancer deaths). It is the most frequent cancer and cause of cancer death in men. * Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC) and classical activating mutations are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors (EGFRi). * Over the last decade, the introduction of tyrosine-kinase inhibitors (TKIs) has showed a remarkable paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, genetic testing is sometimes unavailable. * Data from previous studies that have investigated the value of F-18 FDG PET/CT for predicting EGFR status are conflicting.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DEVICE	F-18 FDGPET/CT	F-18 FDGPET/CT oncology protocol for lung cancer patients

Timeline

• Start date: 2024-10-01
• Primary completion: 2028-10-01
• Completion: 2028-10-01
• First posted: 2024-07-25
• Last updated: 2024-07-25